Literature DB >> 18820243

Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors.

M Gajda, O Camara, S Oppel, T Kroll, C Jörke, S Krauspe, U Hammer, C Rabenstein, M Untch, I B Runnebaum, K Pachmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18820243      PMCID： PMC2733124          DOI： 10.1093/annonc/mdn648

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

Authors:  B P Coudert; L Arnould; L Moreau; P Chollet; B Weber; L Vanlemmens; C Moluçon; N Tubiana; S Causeret; J-L Misset; S Feutray; D Mery-Mignard; J Garnier; P Fumoleau
Journal:  Ann Oncol       Date:  2005-12-06       Impact factor: 32.976

Review 2.  Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.

Authors:  George Lazaridis; George Pentheroudakis; Nicholas Pavlidis
Journal:  Crit Rev Oncol Hematol       Date:  2007-09-04       Impact factor: 6.312

3.  The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.

Authors:  O Camara; M Rengsberger; A Egbe; A Koch; M Gajda; U Hammer; C Jörke; C Rabenstein; M Untch; K Pachmann
Journal:  Ann Oncol       Date:  2007-09       Impact factor: 32.976

4.  Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Authors:  Simone Diermeier; Gábor Horváth; Ruth Knuechel-Clarke; Ferdinand Hofstaedter; János Szöllosi; Gero Brockhoff
Journal:  Exp Cell Res       Date:  2005-01-21       Impact factor: 3.905

5.  Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring.

Authors:  Katharina Pachmann; Oumar Camara; Andreas Kavallaris; Uwe Schneider; Stefanie Schünemann; Klaus Höffken
Journal:  Breast Cancer Res       Date:  2005-10-04       Impact factor: 6.466
  5 in total
  1 in total

1.  Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.

Authors:  Katharina Pachmann; O Camara; T Kroll; M Gajda; A K Gellner; J Wotschadlo; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.